REDWOOD CITY, Calif., Dec. 11, 2017 /PRNewswire/ -- Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration (AMD) and glaucoma, today announced the addition of four key members to its leadership team as it continues to advance its novel ocular treatments through clinical development and evolve into a commercial biotech company.
"I am delighted to welcome Pamela, Dan, Gary and Rajendra to Graybug Vision. Each of these highly talented executives brings deep industry experience and their collective leadership qualities will be instrumental to the growth and development of our team," said Jeffrey L. Cleland, Ph.D., President and CEO of Graybug Vision. "We're excited to bring on board these four experienced individuals with proven track records, who also share our vision, strategy and leadership, as we continue to advance our mission of developing novel products for the treatment of patients with vision-threatening ocular diseases."
Pamela Wapnick, Chief Financial Officer
Ms. Wapnick joins Graybug Vision with over 30 years of finance and operations experience. She was previously at True North Therapeutics, where she was Chief Financial Officer from 2016 to 2017 through the successful completion of a Series D financing and subsequent sale to a third party acquirer. Prior to True North, she held multiple senior financial management roles at Amgen Corporation, including Vice President of Finance for Research and Development, where she held corporate finance responsibility for Amgen's global R&D activities, and was also Vice President and Treasurer of Amgen, where she held responsibility for global capital planning, capital markets and banking activities. Prior to Amgen, she held senior financial management positions in the automotive industry. Ms. Wapnick holds a Bachelors of Arts degree in economics from Wellesley College and an MBA in finance from Columbia Business School.
Dan Salain, Chief Operating Officer
Mr. Salain brings to the team over 28 years of global pharmaceutical experience in manufacturing, supply chain management, strategic sourcing, distribution, quality, operations and business development. He previously served as Senior Vice President of Technical Operations at Ophthotech Corporation and also held the role Global Head of Manufacturing & Supply Chain and Senior Vice President. During the course of his extensive career, he has participated in the successful launch and introduction of over 30 global products including Zenpep®, Lamictal®, Amrix®, Canasa® and Metadate CD®. He has served as Vice President, Global Supply Chain and Manufacturing at Aptalis Pharma where he built a supply chain team and managed manufacturing sites in Italy, France, Canada and the US. Prior to joining Aptalis, he served as the Vice President of Operations at Eurand where he led several technology and licensing deals in addition to running the operations team. Mr. Salain holds a Bachelors of Science degree in chemistry from the University of Indianapolis.
Gary Charbonneau, Senior Vice President, Global Regulatory Affairs
Mr. Charbonneau brings over 25 years of industry experience to Graybug Vision, where he has spent much of his career in Regulatory Affairs and Quality Assurance. Prior to joining Graybug Vision, he was the SVP of Global Regulatory Affairs and Operations at Chase Pharmaceuticals. Before Chase Pharma, Gary spent 11 years at Allergan with his last role as VP of International Regulatory Affairs. During his tenure at Allergan he held several leadership roles within the Regulatory Affairs organization and was integral in building the Global Regulatory Affairs organization. Over the course of his career he has worked within various therapeutic areas including ophthalmology, urology, dermatology, and neurology. He has also held various roles at Amgen, Roche Bioscience, and Novo Nordisk early in his career. Mr. Charbonneau received his Bachelors of Science degree in Biological Science from California Polytechnic State University, San Luis Obispo and his Masters degree in Regulatory Science from the University of Southern California.
Rajendra Mohabir, PhD, Vice President, Product Development & Alliance Management
Dr. Mohabir brings over 25 years of industry experience in research and drug development to Graybug Vision. He has previously held senior positions at Syntex Discovery Research, Roche, Genentech, and Amgen. He has provided leadership to many product development teams primarily in the areas of cardiovascular and oncology, and also lower urinary tract disorders, chronic pain and respiratory disorders. Dr. Mohabir has provided product development leadership for several currently marketed products, including Pulmozyme®, TNKase®/Activase®, Aranesp®, and Neupogen®/Neulasta®. He also has experience working at smaller biotech companies, including LoneStar Heart as Vice President of Regenerative Therapies and at Versartis, where he was Vice President of Product Development and Alliance Management, where he led the product development team for a long-acting growth hormone, Somavaratan, from Phase 1b to Phase 3 clinical trials. Dr. Mohabir received his Bachelors of Science degree in Microbiology and Immunology from McGill University, and his PhD in Pharmacology from Dalhousie University. He completed his post-doctoral work in Cardiovascular Medicine at Stanford University School of Medicine.
About Graybug Vision
Graybug Vision is developing novel products for the treatment of people with ocular diseases. The company's proprietary injectable products are designed to enable less frequent administration and to reduce the burden of treatment for patients with ocular diseases. The company's lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD. Graybug Vision has developed a library of compounds to treat glaucoma, a leading cause of progressive, irreversible vision loss worldwide, by lowering intraocular pressure alone or in combination with neuroprotection when injected twice per year. For more information, please visit www.graybug.com.
SOURCE Graybug Vision, Inc.